Hospital Anti-Infective Demand Will Face Reimbursement Headwinds Yet Ultimately Support Modest Upside

Catalysts

About CorMedix

CorMedix develops and commercializes specialty therapies that prevent and treat life threatening infections in high risk hospital and clinic patients.

What are the underlying business or industry changes driving this perspective?

• Although DefenCath has shown record adoption in outpatient hemodialysis, the shift from TDAPA to a post add on reimbursement model could compress pricing and slow revenue growth in the second half of 2026 if CMS methodologies or proposed legislative changes do not materialize favorably. This could pressure top line expansion and EBITDA leverage.
• Although the growing burden of antimicrobial resistance and invasive fungal infections supports long term demand for hospital based anti infectives like Rezzayo, any delay, negative outcome or modest differentiation in the ReSPECT prophylaxis Phase III data in 2026 could limit uptake versus entrenched standards of care. This could cap the expected revenue and earnings contribution from this large targeted market.
• While the expansion of DefenCath into total parenteral nutrition patients addresses a substantial unmet need with a sizeable addressable market, slower than planned Nutri Guard trial enrollment or inconclusive Phase III results could push out launch timing. This could reduce the anticipated diversification of revenue and margin mix beyond hemodialysis.
• Although the Melinta acquisition provides a broader promoted portfolio and potential cost synergies, integration risks and system harmonization delays into 2026, along with possible underperformance of the legacy Melinta brands, could mean that projected synergy savings and operating margin improvements are not fully realized on the current time line.
• While strategic optionality around assets like Talphera's late stage critical care product and the Niyad opportunity could create new high value critical care revenue streams, overpaying for acquisitions, needing higher than expected commercial investment or facing weaker than anticipated clinical outcomes could dilute returns and weigh on future net income growth.

Assumptions

This narrative explores a more pessimistic perspective on CorMedix compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts. How have these above catalysts been quantified?

• The bearish analysts are assuming CorMedix's revenue will grow by 12.3% annually over the next 3 years.
• The bearish analysts assume that profit margins will shrink from 75.8% today to 20.9% in 3 years time.
• The bearish analysts expect earnings to reach $63.4 million (and earnings per share of $0.75) by about December 2028, down from $162.5 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $299.3 million.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 26.1x on those 2028 earnings, up from 6.1x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 19.9x.
• The bearish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.96%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• The transition from TDAPA to the post add on reimbursement model in the second half of 2026 may drive meaningful price compression for DefenCath, which could slow volume growth in outpatient hemodialysis and pressure long term revenue and net margins.
• If CMS maintains a conservative utilization methodology for the post TDAPA add on, or proposed legislation to extend and enhance TDAPA does not pass, DefenCath may capture a smaller share of reimbursement than management anticipates. This could reduce future earnings power and limit EBITDA expansion.
• Rezzayo prophylaxis data in the Phase III ReSPECT trial may fail to show a clinically meaningful advantage over the entrenched standard of care despite secular growth in invasive fungal infections. This would undermine expectations for a large new antifungal revenue stream and constrain earnings diversification.
• The Phase III Nutri Guard trial in total parenteral nutrition patients could face enrollment delays, regional execution challenges or inconclusive outcomes despite high CLABSI rates in this population. This would defer or diminish the anticipated TPN indication and weigh on long term revenue mix and margin improvement.
• Integration of Melinta and potential future acquisitions such as Talphera could fall short of the projected synergy targets as systems consolidation stretches into 2026, or legacy brands underperform in a competitive anti infective landscape. This would erode operating leverage and constrain sustained growth in net income.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for CorMedix is $14.0, which represents up to two standard deviations below the consensus price target of $19.0. This valuation is based on what can be assumed as the expectations of CorMedix's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $22.0, and the most bearish reporting a price target of just $14.0.
  
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2028, revenues will be $303.6 million, earnings will come to $63.4 million, and it would be trading on a PE ratio of 26.1x, assuming you use a discount rate of 7.0%.
  
• Given the current share price of $12.53, the analyst price target of $14.0 is 10.5% higher. Despite analysts expecting the underlying business to decline, they seem to believe it's more valuable than what the market thinks.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.